Cyproterone Acetate
Cyproterone acetate is represented here only in combination with ethinylestradiol. Direct regulator sources identify the Diane 35 formulation as 2 mg cyproterone acetate with 35 micrograms of ethinylestradiol, used in specific androgen-sensitive skin and hair contexts.
Ginette-35
Androgen-dependent Acne, Hirsutism
0.035mg + 2mg
Developed to mitigate androgen-related acne and hair growth to support clear skin and target hormone normalisation.
Key points
- Neither attached product contains cyproterone acetate alone.
- Diane 35 and Ginette-35 share the same two active ingredients.
- The formulation has antiandrogenic and hormonal contraceptive activity.
- Venous thromboembolism is a material formulation-specific risk.
A combination-only ingredient page
Diane 35 and Ginette-35 are both cyproterone acetate and ethinylestradiol tablets. Their taxonomy connects them with androgen-dependent acne and hirsutism in women’s health.
The catalogue strength string contains 0.035 mg and 2 mg. Authority sources make the mapping explicit: ethinylestradiol is 0.035 mg, equivalent to 35 micrograms, and cyproterone acetate is 2 mg.
Clinical identity and safety
European and UK regulator material describes this low-dose formulation for moderate to severe acne related to androgen sensitivity or for hirsutism in women of reproductive age. Its hormonal contraceptive action belongs to the combined product, not to cyproterone acetate considered in isolation.
Regulatory review also confirms a venous thromboembolism risk. That risk makes individual medical history, concurrent hormonal medicines and new symptoms important parts of clinical assessment.